Precision Medicine Group

About Precision Medicine Group

Established in 2012 by founders Mark Clein and Ethan D. Leder, Precision Medicine Group (PMG) operates as a specialized services organization dedicated to the life sciences sector. The company was founded on the premise of accelerating the development and commercialization of new therapies, particularly in the burgeoning field of precision medicine. Clein, serving as CEO, brings a background from his previous role as CEO of a healthcare private equity platform, while Leder, the Executive Chairman, has a history of co-founding and leading successful healthcare service companies, including United BioSource Corporation, which he also co-founded with Clein. This prior entrepreneurial experience in building and scaling life science service businesses provides a foundational expertise for PMG's strategic direction.

PMG's business model is centered on providing a comprehensive suite of services that support pharmaceutical and biotech companies throughout the entire product lifecycle, from preclinical development to post-launch commercialization. The firm operates through distinct business units, including Precision for Medicine and Precision Value & Health, to offer integrated solutions. Its client base consists of life science innovators, ranging from small biotech startups to large pharmaceutical corporations, who are developing next-generation treatments that target specific patient populations. The company generates revenue by providing these specialized, knowledge-based services, which include clinical trial support, advanced laboratory services for biomarker identification, regulatory consulting, and market access strategies. This integrated approach is designed to de-risk and streamline the complex path to market for novel therapies.

A core component of PMG's service offering is its focus on biomarker-driven clinical development. Precision for Medicine, a key part of the group, delivers a range of services including specialized biomarker assays, cell and gene therapy logistics through its Project Farma acquisition, and global clinical trial management. This allows clients to identify patient populations most likely to respond to a treatment, thereby improving clinical trial success rates and demonstrating value to payers. For example, its acquisition of ApoCell in 2015 enhanced its capabilities in biomarker sample collection and analysis. By combining scientific expertise, operational scale, and strategic market insights, the company helps its partners navigate the scientific, regulatory, and commercial hurdles inherent in bringing targeted therapies to patients. This is further supported by a growth strategy that involves both organic development and strategic acquisitions of companies with critical capabilities, such as the 2020 acquisitions of Project Farma and Stern Investor Relations.